anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Surgical treatment of symptomatic benign prostatic hyperplasia (BPH) has seen an evolution during the last decades. On one hand, en-bloc HoLEP emerged as a valid endoscopic treatment regardless prostate size. On the other hand, robot-assisted simple prostatectomy (RASP) has gained attention in larger prostates showing encouraging results. Herein, for the first time in the scientific scenario, we sought to compare the outcomes of RASP and en-bloc HoLEP cases after propensity-score matching (PSM) analysis.
METHODS: We retrospectively queried our prospectively database of patients treated with HoLEP or RASP between 2017 and 2022 among two high-volume centers. PSM was applied based on the International Prostate Symptom Score (IPSS) questionnaire, prostate volume and max-flow rate. All procedures were performed by a single surgeon per center. Outcomes were assessed at 1, 3, and 6-month postoperatively and therefore annually. Trifecta definition was used to assess "success" in surgical procedures and was defined as the contemporary presence of: a) no postoperative complications within the first postoperative month; b) 1-month postoperative Qmax >15 ml/s and c) no urinary incontinence at 3-month evaluation.
RESULTS: Overall, 48 HoLEP and 47 RASPs were matched. Operative time, hospitalization time (median 4 vs 5 days) and catheterization time (median 3 vs 2 day) were found to be shorter in the HoLEP group as compared to the counterpart (p < 0.05). Early postoperative complication rate was also lower in the HoLEP cohort (6.2% vs 12.6%; p = 0.03) as well as postoperative haemoglobine blood level drop (1.4 vs 2.4 g/dL; p = 0.03). On the other hand, postoperative antegrade ejaculation (55.3% vs 6.8%) 1-month max flow (median 28 vs 24 ml/sec) and continence rates (0% vs 20.8%) favored RASP (p < 0.05). Overall, Trifecta rate was similar in the two groups (76.1% vs 82.6%).
CONCLUSION: Both HoLEP and RASP are safe and effective treatments for symptomatic BPH. HoLEP demonstrated to have lower perioperative risks while is affecting by a higher probability of transient early UI. On the other hand, RASP is more effective in reducing postoperative ejaculatory dysfunction.
BACKGROUND: The attention towards the relationship between chronic obstructive pulmonary disease (COPD) and dietary intake is escalating. However, the effects of dietary niacin on COPD in middle and older individuals remains unclear. This study aimed to illuminate the connection between dietary niacin intake and COPD.
METHODS: This cross-sectional study analyzed 7,170 participants from the National Health and Nutrition Examination Survey (NHANES) spanning the years 2013 to 2018. Participants were categorized into four groups based on quartiles of dietary niacin intake. To examine the association between covariates, dietary niacin intake, and COPD, we employed univariate analysis and multivariate logistic regression equations. Additionally, restricted cubic splines were utilized to assess linearity. Furthermore, we conducted stratified and interaction analyses to evaluate the stability of the relationship in diverse subgroups.
RESULTS: Among the 7,170 participants, 11.6% (834/7170) were diagnosed with COPD. The multivariable adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for COPD were 0.96 (95% CI: 0.77-1.19, p = 0.706), 0.78 (95% CI: 0.62-0.99, p = 0.038), and 0.76 (95% CI: 0.57-1.00, p = 0.047), respectively, when comparing the second, third, and fourth quartiles of niacin intake levels to the lowest quartile (p for trend = 0.017). An inverse association was observed between the occurrence of COPD and dietary niacin intake (nonlinear: p = 0.347). Stratified analyses revealed no significant differences or interactions.
CONCLUSION: Our findings suggest a potential link between increased dietary niacin intake and a decreased prevalence of COPD.
PURPOSE: The effects of lacking exercise due to increased sedentary behavior on physical and mental health are attracting attention. We developed an exercise program for sedentary behavior in desk workers and verified whether decreased body pain and weakness and improved subjective health are short-term effects.
SUBJECTS AND METHODS: We developed a 3-min exercise program comprising three among four types of exercises; standing on one leg (1 min on each side), squats (1 min), stretching (1 min), and deep breathing with eyes closed (1 min). The exercise program was performed in the morning and afternoon for 2 months (41 days) (3 types × twice daily × 41 days = 246 times) by 94 employees of University A. For easier implementation, radio exercises (part 1), widely recognized in Japan, were performed in the morning and afternoon before work. Participants were asked about their attributes, work situation, physical and mental conditions before and after implementation, and evaluation of the exercise program after implementation.
RESULTS: Exercise records and questionnaire responses were collected from 87 participants. The median number of exercises was 83 (interquartile range; 16-128). The participants were divided into two groups based on the median values. The level of lower back pain and friendship scores had an interaction and improved in the group that performed the exercise more frequently. A receiver operating characteristic curve was drawn based on the relationship between the group whose level of lower back pain was reduced by at least 2 of 11 points and that who did not, and the number of exercises. The cutoff value was 70 times, suggesting that performing exercise ≥ 70 times for 41 days decreased lower back pain. To continue implementing the exercise program, it was necessary to use free time, maintain motivation, and create a sense of unity in the workplace.
CONCLUSIONS: We created an exercise program comprising four types of exercise for sedentary behavior in desk workers, which is performed in the morning and afternoon for 2 months. Improvements were seen in the degree of lower back pain and friendship score.
How to prepare and take 2 NITYR tablets using a 5 mL oral syringe:

Step 16. After use, remove the plunger from the oral syringe barrel. Rinse the oral syringe with water after each use and let it dry. Do not replace the plunger into the barrel of the oral syringe until ready to use again to allow it to dry. Do not throw away the oral syringe.

  
If you are not taking the water and NITYR tablets suspension as soon as it is prepared, complete steps 1 through 5. When you are ready to take the suspension, complete steps 6 through 16.
Multimodal perception is the predominant means by which individuals experience and interact with the world. However, sensory dysfunction or loss can significantly impede this process. In such cases, cross-modality research offers valuable insight into how we can compensate for these sensory deficits through sensory substitution. Although sight and hearing are both used to estimate the distance to an object (e.g., by visual size and sound volume) and the perception of distance is an important element in navigation and guidance, it is not widely studied in cross-modal research. We investigate the relationship between audio and vibrotactile frequencies (in the ranges 47-2,764 Hz and 10-99 Hz, respectively) and distances uniformly distributed in the range 1-12 m. In our experiments participants mapped the distance (represented by an image of a model at that distance) to a frequency via adjusting a virtual tuning knob. The results revealed that the majority (more than 76%) of participants demonstrated a strong negative monotonic relationship between frequency and distance, across both vibrotactile (represented by a natural log function) and auditory domains (represented by an exponential function). However, a subgroup of participants showed the opposite positive linear relationship between frequency and distance. The strong cross-modal sensory correlation could contribute to the development of assistive robotic technologies and devices to augment human perception. This work provides the fundamental foundation for future assisted HRI applications where a mapping between distance and frequency is needed, for example for people with vision or hearing loss, drivers with loss of focus or response delay, doctors undertaking teleoperation surgery, and users in augmented reality (AR) or virtual reality (VR) environments.
The primary study endpoint is objective response rate. The study has been designed following Simon's test, with a p1-p0=0.15. p1 is the optimum level of activity of the experimental treatment (exemestane), and p0 is the minimum expected activity. In this study, p1 is 25% (25% of RR) and p0 is 10% (10% of RR). With an alpha error of 0.05 and a beta error of 0.1, Simon test establishes a first step of 21 patients per treatment arm. If at least 2 objective responses are observed in exemestane arm, recruitment will continue until 100 patients have been recruited. After this second recruitment phase, at least 7 objective responses must be observed to confirm the expected exemestane level of activity.
Excessive activation of the mineralocorticoid receptor (MR) is implicated in cardiovascular and renal disease. Decreasing MR activation with MR antagonists (MRA) is effective to slow chronic kidney disease (CKD) progression and its cardiovascular comorbidities in animal models and patients. The present study evaluates the effects of the MR modulator balcinrenone and the MRA eplerenone on kidney damage in a metabolic CKD mouse model combining nephron reduction and a 60% high-fat diet. Balcinrenone and eplerenone prevented the progression of renal damages, extracellular matrix remodeling and inflammation to a similar extent. We identified a novel mechanism linking MR activation to the renal proteoglycan deposition and inflammation via the TLR4 pathway activation. Balcinrenone and eplerenone similarly blunted this pathway activation.
Induction of anesthesia in hemodynamically compromised patients is a challenge for every anesthetist. Most of the intravenous induction agents have a negative effect on arterial blood pressure and cardiac output. Theoretically, the "ideal" emergency induction intravenous anesthetic should achieve rapid hypnosis and maintain the hemodynamic stability Ketamine has been reported as an induction anesthetic with a sympathomimetic activity. In patients with intact autonomic nervous system ketamine increases heart rate, cardiac output, and arterial blood pressure (ABP). Despite its sympathomimetic activity in hemodynamically stable patients, the hemodynamic response to ketamine in unstable cardiovascular conditions is not clear No studies to the best of our knowledge compared Ketamine and low dose thiopental in rapid sequence induction of anesthesia in hemodynamically unstable patients.

In this study, patients with severe sepsis or septic shock scheduled for surgery will be assigned to receive either ketamine or thiopental for induction of anesthesia. After induction of anesthesia, endotracheal tube will be inserted aided by succinyl choline. Invasive blood pressure will be monitored through a transducer connected to arterial catheter. Electrical velocimetry (cardiometry) device will be used for non-invasive monitoring of cardiac output and stroke volume.
The invention provides therapeutic methods, kits, and pharmaceutical compositions for treating cancer using a combination of (i) a first anti-cancer agent, and (ii) an agent that increases the rate of clearance (such as metabolism) of the first anti-cancer agent, and (iii) optionally a second anti-cancer agent. The invention also provides therapeutic methods, kits, and pharmaceutical compositions for treating cutaneous abnormalities comprising administering an angiogenesis inhibitor and an agent capable of enhancing the efficacy of the angiogenesis inhibitor. In some embodiments, a pulsed dosing is used. The invention also provides therapeutic methods and pharmaceutical compositions for treating conditions associated with abnormal extracellular matrix (ECM). The invention is based on the discovery that that modulating abnormal ECM using a first agent improves the delivery and/or efficacy of a second agent in ameliorating an abnormal ECM associated condition. Also disclosed are methods for identifying agents capable of modulating the abnormal ECM.
The invention provides methods for identification and determination of target-specific folding sites in peptides and proteins, including a method for determining a secondary structure binding to a target of interest within a known parent polypeptide that binds to the target of interest. In one embodiment of the invention, a residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between two adjacent residues in a known primary sequence of a peptide or protein. The resulting sequence, which includes a minimum of the residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion and two residues on the amino terminus side thereof, is complexed with a metal ion, thereby forming a metallopeptide. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide demonstrating binding or functional activity is selected. The invention further provides methods to determine the specific sequence and local three-dimensional structure of that portion of peptides or proteins that bind to a receptor or target of interest, or mediate a biological activity of interest and methods to determine the pharmacophore of receptors or targets of interest. The invention provides for defined pharmacophores or receptors or targets of interest and directed libraries for identification and determination of target-specific folding sites in peptides and proteins and for identification and determination of pharmacophores of receptors or targets of interest.
The main purpose of this study is to determine if it is possible to precondition competitive swimmers and improve their exercise performance to provide further insight into the physiological mechanisms through which preconditioning may function. With four 5 minute inflation cycles of a blood-pressure cuff, we will induce skeletal muscle ischemia which is known to be a powerful method of preconditioning. Each swimmer will be blinded to the expected effect and randomly assigned to real preconditioning versus the sham intervention which will consist of four 5 minute cycles of blood pressure cuff inflation to 10mmHg. During a subsequent training session, the subjects will receive the intervention they have not received during the previous test session. Therefore, each subject will be part of both study groups and will serve as their own control. To evaluate the exercise performance, the subjects will perform an incremental swimming test protocol based on methods developed and reported by a member our research team. Swimming velocity, blood lactate level, heart rate, breathing frequency, dyspnoea and oxygen saturation will be measured during incremental exercise. Finally, we would like to determine the preconditioning effect of regular exercise training in an animal model.

Exercise performance is thought to be limited by skeletal, cardiac and respiratory muscle fatigue associated with episodes of exercise induced arterial hypoxemia. Preconditioning is defined as a period of brief lack of oxygen or ischemia in a tissue that protects the heart or any other organ from another sustained episode of ischemia. Preconditioning is believed to improve exercise performance by protecting the skeletal, cardiac and respiratory muscles against decreased oxygen and by-products of anaerobic metabolism that may limit an individual's exercise performance. Elite athletes, such as highly trained swimmers, may provide the research team with the opportunity to evaluate the effect of preconditioning during local tissue hypoxia and anaerobic metabolic by-products in healthy adolescents, which is otherwise not possible. With this study, we will show if it is possible to precondition competitive swimmers and improve their exercise performance using ischemia of the limb as a preconditioning stimulus.
The present invention relates to a boat-fruited sterculia seed and ice flower buccal tablet and a preparation method thereof. The buccal tablet is prepared from the extracting solutions of boat-fruited sterculia seed, perilla, green tea and liquorice root, sucrose and rock candy seed according to the proportion in the formula. The preparation method comprises the following steps: preparing the extracting solutions; sufficiently stirring the prepared extracting solutions according to the proportion, and adding the extracting solutions to syrup; putting the syrup in a cavity with the coated rock candy seed in a rock candy forming machine; pumping the syrup to vacuum for 72 hours at the temperature of 60 to 70DEG C; after drying the syrup by releasing a mould, putting the syrup in a film forming pot containing a mint film forming solution for coating a film; and drying, packaging and warehousing the coated syrup. The buccal tablet has obvious effects on adaptation diseases and has high cure rate; the total effective rate is 100%. The shelf life of the buccal tablet is three years. The buccal tablet provides the preferred medicine for patients with acute and chronic sphagitis, stomatitis, hoarse throat and cough.
PURPOSE: To obtain a raw material for skin preparation for external use, containing a hydrolyzate derived from wheat and a saccharide in a specific ratio, maintaining sufficient moisture retention in human skin and hair even in a low-humidity environment, showing no excessive moisture retention even in a high-humidity environment. CONSTITUTION: This raw material for skin preparation for external use contains 5-30 pts.wt. of a water-soluble saccharide obtained by hydrolyzing wheat starch based on 100 pts.wt. of a water-soluble hydrolyzate of wheat protein prepared from wheat. The substance containing 5-30 pts.wt. of the saccharide based on 100 pts.wt. of the hydrolyzate of wheat protein, for example, is obtained by adjusting degree of washing with water in a process for washing wheat flour (preferably high-gluten wheat flour) with water, washing away starch and concentrating protein to prepare gluten, making the ratio of protein to glucide proper and simultaneously hydrolyzing both the protein and glucide with an acid catalyst. Advantageously, the main raw material is only readily available wheat.
Inclusion criteria:1. Adults over 20 years-old. 2. The patient who meets the diagnostic criteria of overactive bladder or underactive bladder. 3. The patient who capable to complete 3-days voiding diary and the questionnaire. Exclusion criteria: 1. The patient has severe stress urinary incontinence, severe pelvic organ prolapse, acute urinary tract infection, urolithiasis, or urinary tract malignancy. 2. The patient who has active skin disease on legs or not suitable for leg local injection. 3. Pregnant women. Method: 40 overactive bladder patients and 40 underactive bladder patients. The patients will receive 5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks, then the patients will be followed up once-a-month for 3 months. OverActive Bladder Symptom Score(OABSS), Core Lower Urinary Tract Symptom score(CLSS) questionnaire, 3-days voiding diary, and urine nerve growth factor are used for assessment.
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a significant public health problem characterized by persistent airflow limitation. Despite previous research into the pathogenesis of COPD, a comprehensive understanding of the cell-type-specific mechanisms in COPD remains lacking. Recent studies have implicated Rab GTPases in regulating chronic immune response and inflammation via multiple pathways. In this study, the molecular regulating mechanism of RAB32 in COPD was investigated by multiple bioinformatics mining and experimental verification.
METHODS: We collected lung tissue surgical specimens from Zhongshan Hospital, Fudan University, and RT-qPCR and western blotting were used to detect the expression of Rabs in COPD lung tissues. Four COPD microarray datasets from the Gene Expression Omnibus (GEO) were analyzed. COPD-related epithelial cell scRNA-seq data was obtained from the GSE173896 dataset. Weighted gene co-expression network analysis (WGCNA), mfuzz cluster, and Spearman correlation analysis were combined to obtain the regulatory network of RAB32 in COPD. The slingshot algorithm was used to identify the regulatory molecule, and the co-localization of RAB32 and GPRC5A was observed with immunofluorescence.
RESULTS: WGCNA identified 771 key module genes significantly associated with the occurrence of COPD, including five Rab genes. RAB32 was up-regulated in lung tissues from subjects with COPD as contrast to those without COPD on both mRNA and protein levels. Integrating the results of WGCNA, Mfuzz clusters, and Spearman analysis, nine potential interacting genes with RAB32 were identified. Among these genes, GPRC5A exhibited a similar molecular expression pattern to RAB32. Co-expression density analysis at the cell level demonstrated that the co-expression density of RAB32 and GPRC5A was higher in type I alveolar epithelial cells (AT1s) than in type II alveolar epithelial cells (AT2s). The immunofluorescence also confirmed the co-localization of RAB32 and GPRC5A, and the Pearson correlation analysis found the relationship between RAB32 and GPRC5A was significantly stronger in the COPD lungs (r = 0.65) compared to the non-COPD lungs (r = 0.33).
CONCLUSIONS: Our study marked endeavor to delineate the molecular regulatory axis of RAB32 in COPD by employing diverse methods and identifying GPRC5A as a potential interacting molecule with RAB32. These findings offered novel perspectives on the mechanism of COPD.
Group 1 consists of 59 participants with a fractioned exhaled nitric oxide ≥ 45 ppb and ≥ 3 exacerbations / year (biologic eligible). Group 2 consists of 59 participants with a fractioned exhaled nitric oxide ≥ 45 ppb and \< 3 exacerbations / year (biologic ineligible).
Hemofiltration systems and methods to treat an Inflammatory Mediator Related Disease in a patients, including chronic and acute diseases, may include a hemofilter and an adsorptive device. The systems and methods may further include one or more therapeutic agents administered to the patient. The hemofilter removes ultrafiltrate from a blood stream extracted from the patient to create a filtered blood stream and an ultrafiltrate stream. The adsorptive device may include one or more adsorbent materials and may be used to adsorb inflammatory mediators from the ultrafiltrate stream received from the hemofilter to create a post adsorption ultrafiltrate stream. The post adsorption ultrafiltrate stream may be selectively combined with the filtered blood stream and together with the filtered blood stream may be returned to the mammal. Other systems and methods are disclosed.